- SWTX Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
S-8 Filing
SpringWorks Therapeutics (SWTX) S-8Registration of securities for employees
Filed: 24 Feb 22, 5:20pm
As filed with the Securities and Exchange Commission on February 24, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
SPRINGWORKS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 83-4066827 | |
(State or other jurisdiction of incorporation or organization) |
| (I.R.S. Employer Identification Number) |
100 Washington Blvd
Stamford, CT 06902
(203) 883-9490
(Address of Principal Executive Offices)
SpringWorks Therapeutics, Inc. Amended and Restated 2019 Stock Option and Equity Incentive Plan
SpringWorks Therapeutics, Inc. 2019 Employee Stock Purchase Plan
(Full Title of the Plans)
Saqib Islam
Chief Executive Officer
100 Washington Blvd
Stamford, CT 06902
(203) 883-9490
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Kingsley Taft
Sarah Ashfaq
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x | Accelerated filer ¨ | |
Non-accelerated filer ¨ | Smaller reporting company ¨ | |
Emerging growth company ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE
This Registration Statement on Form S-8 registers additional shares of the Registrant’s common stock, par value $0.0001 (the “Common Stock”) under the Registrant’s Amended and Restated 2019 Stock Option and Equity Incentive Plan (the “Equity Incentive Plan”) and 2019 Employee Stock Purchase Plan (the “ESPP”).
The number of shares of Common Stock reserved and available for issuance under the Equity Incentive Plan is subject to an automatic annual increase on each January 1, by an amount equal to five percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or such lesser number of shares of Common Stock as determined by the Administrator of the Equity Incentive Plan (as defined in the Equity Incentive Plan). Accordingly, on January 1, 2022, the number of shares of Common Stock reserved and available for issuance under the Equity Incentive Plan increased by 2,462,400 shares.
The number of shares of Common Stock reserved and available for issuance under the ESPP is subject to an automatic annual increase on each January 1, by the lesser of (i) 1% of the outstanding shares on the immediately preceding December 31, (ii) 663,229 shares of Common Stock, or (iii) such amount as determined by the Administrator of the ESPP (as defined in the ESPP). Accordingly, on January 1, 2022, the number of shares of Common Stock reserved and available for issuance under the ESPP increased by 492,480 shares.
This Registration Statement on Form S-8 registers these additional 2,954,880 shares of Common Stock. The additional shares are of the same class as other securities relating to the plans for which the Registrant’s registration statements filed on Form S-8 (Registration No. 333-234365) on October 29, 2019, March 23, 2020 (Registration No. 333-237350), and February 25, 2021 (Registration No. 333-253531) is effective. The information contained in the Registrant’s registration statement on Form S-8 (Registration No. 333-234365) is hereby incorporated by reference pursuant to General Instruction E.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Stamford, Connecticut on the 24th day of February, 2022.
SPRINGWORKS THERAPEUTICS, INC. | |||
By: | /s/ Saqib Islam | ||
Saqib Islam, J.D. | |||
Chief Executive Officer and Director |
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints Saqib Islam as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.
Name | Title | Date | ||
/s/ Saqib Islam | Chief Executive Officer, Director | February 24, 2022 | ||
Saqib Islam, J.D. | (Principal Executive Officer) | |||
/s/ Francis I. Perier, Jr. | Chief Financial Officer | February 24, 2022 | ||
Francis I. Perier, Jr. | (Principal Financial Officer) | |||
/s/Michael P. Nofi | Chief Accounting Officer | February 24, 2022 | ||
Michael P. Nofi | (Principal Accounting Officer) | |||
/s/ Daniel S. Lynch | Chairman | February 24, 2022 | ||
Daniel S. Lynch, M.B.A. | ||||
/s/ Alan Fuhrman | Director | February 24, 2022 | ||
Alan Fuhrman | ||||
Director | February 24, 2022 | |||
Julie Hambleton, M.D. | ||||
/s/ Freda Lewis-Hall | Director | February 24, 2022 | ||
Freda Lewis-Hall, M.D., DFAPA | ||||
/s/ Jeffrey Schwartz | Director | February 24, 2022 | ||
Jeffrey Schwartz, M.B.A. | ||||
/s/ Stephen Squinto | Director | February 24, 2022 | ||
Stephen Squinto, Ph.D. |
EXHIBIT INDEX
* | Filed herewith. |